Azatadine
Azatadine (Optimine) is a first-generation antihistamine and anticholinergic that was launched by Schering-Plough in 1973.[1][2]
Clinical data | |
---|---|
Trade names | Optimine |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
Pregnancy category |
|
ATC code | |
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C20H22N2 |
Molar mass | 290.410 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
| |
(verify) |
It was patented in 1967.[3] It has been succeeded by both loratadine and desloratadine.[4]:53 and marketing approvals have been widely withdrawn.[5][6][7][8]:290[9]
See also
References
- Katelaris, C. (1990). "Comparative effects of loratadine and azatadine in the treatment of seasonal allergic rhinitis". Asian Pacific Journal of Allergy and Immunology. 8 (2): 103–107. PMID 1982614.
- Small, P.; Barrett, D.; Biskin, N. (1990). "Effects of azatadine, terfenadine, and astemizole on allergen-induced nasal provocation". Annals of Allergy. 64 (2 Pt 1): 129–131. PMID 1968324.
- Azatadine, Villani, F. J.; Caldwell, W. U.S. Patent 3,326,924 (1967).
- Horak F. Antialergic and Vasoactive Drugs for Allergic Rhinitis. Chapter 4 in Allergy Frontiers:Therapy and Prevention. Volume 5 of Allergy Frontiers. Eds Pawankar R et al Springer Science & Business Media, 2010 ISBN 9784431993629
- Drugs.com Drugs.com listing for Azatadine Page accessed July 3, 2015
- Federal Register 2005 Food and Drug Administration Docket No.2005N-0058: Hospira, Inc. et al.; Withdrawal of Approval of 76 New Drug Applications and 60 Abbreviated New Drug Applications 70 FR 10651
- Federal Register 2007 Food and Drug Administration Docket No. 2004P-0262: Withdrawal of Approval of 128 Suitability Petitions 72 FR 8184
- Department of Economic and Social Affairs of the United Nations Secretariat Consolidated List of Products Whose Consumption and/or Sale Have Been Banned, Withdrawn, Severely Restricted or not Approved by Governments Twelfth Issue: Pharmaceuticals United Nations – New York, 2005
- FDA OGD Suitability Tracking Report (Sorted by Drug Name) Page accessed July 3, 2015
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.